-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The centralized disclosure of the 2021 annual report notice has come to an end
.
According to data from Oriental Fortune.
com, 58 listed machinery companies have announced their 2021 performance forecasts, accounting for 57.
43% of the total listed machinery companies
.
In general, the medical device industry, as one of China's high-tech industries, has a strong performance in 2021: among the listed companies that have announced their performance forecasts, 42 have pre-increased their performance, and nearly half of the companies have net profit attributable to their parent companies.
is expected to double
.
As of press time, 82 listed machinery companies have released the 2021 annual report appointment disclosure time, which will enter the peak period of annual report disclosure from mid-March to the end of April
.
The IVD field is unrivaled, and high-end products are shining brightly.
Judging from the expected year-on-year increase in net profit, the four companies of Rejing Bio, Zhijiang Bio, Kaili Medical, and Jiu'an Medical are expected to increase their performance by more than 3 times in 2021; Jiuqiang Bio , Kailitai, Aohua Endoscopy, Oriental Bio, Mingde Bio, Wantai Bio and other performance increased by more than 200%
.
Specifically, the substantial increase in overseas demand for new crown antigen detection reagents has led to a substantial increase in the performance of listed machinery companies in the IVD field
.
Rejing Bio is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%; Zhijiang Bio is expected to achieve a net profit of 930 million yuan in 2021, a year-on-year increase of 1705.
1%.
When analyzing the changes in performance, the main reason for the increase in profits was attributed to the approval of the novel coronavirus antigen detection kit abroad, which led to the explosive growth of the company's foreign trade orders and a major breakthrough in performance
.
The latest data from the Medical Insurance Chamber of Commerce shows that as of January 27, 2022, a total of 783 companies have produced new coronavirus detection reagents that have obtained foreign standard certification or registration
.
Jiu'an Medical, which has been eye-catching in the capital market since December last year, also benefited from the surge in sales of the new coronavirus (SARS-CoV-2) antigen home self-testing OTC kit products in the US market, which led to a substantial increase in operating performance in 2021.
It is expected to achieve a net profit of 900 million to 1.
2 billion yuan in the whole year, a year-on-year increase of 271.
4% to 395.
19%
.
In addition to the significant increase in foreign trade orders and related income of overseas new crown detection reagents due to the impact of the Delta and Omicron epidemics, some medical device companies have taken new steps in high-quality innovation and development, with considerable benefits
.
Taking Kaili Medical as an example, according to the statistics of Zhongcheng Digital, in 2021, a total of 4,394 purchasing units were monitored to announce the bidding results of medical endoscopes.
In terms of the winning amount of the winning brands, Kaili Medical ranked seventh
.
According to the forecast of Kaili Medical, the net profit for the whole year is 205 million to 255 million yuan, a year-on-year increase of 543.
12% to 651.
2%, and the revenue scale may reach a record high
.
As the products gain more clinical approvals, Aohua Endoscopy, another leading domestic endoscope company, will also deliver a satisfactory answer: in 2021, it is expected to achieve a net profit of 56 million to 63 million yuan, a year-on-year increase of 202.
54% to 240.
36%
.
Table 1 Some 2021 annual reports are expected to increase the performance of listed machinery companies.
The price of epidemic prevention products has returned, and centralized procurement has caused pain.
Compared with the unique scenery of foreign trade of new crown detection reagents, epidemic prevention products will gradually return to normal in 2021
.
According to statistics, 16 of the 58 listed machinery companies that have announced their 2021 performance forecasts have reported losses
.
Among them, Ogilvy Medical, which takes protective products as one of its main businesses, will be affected by the epidemic in 2020, and the price and volume of protective products will increase, resulting in a sharp increase in performance in 2020
.
In 2021, with the global epidemic prevention and control entering the normalization stage, Ogilvy Medical adjusted the business proportion of protective products, and the price and volume returned to normal levels.
62.
68%～-59.
83%
.
At the same time, with the continuous advancement of the procurement of high-value medical consumables, the coverage of centralized procurement has gradually expanded
.
In addition to the centralized procurement of coronary stents and artificial joints carried out by the state, the bidding work at the provincial level also involves related products such as intraocular lenses and coronary balloons
.
However, while the marketing costs of the winning products are reduced, they also face the test of profitability
.
For example, Kailitai predicts that it is expected to achieve a net profit of 140 million to 200 million yuan for the whole year, a year-on-year increase of 210.
64% to 258.
06%, but in the performance forecast, it also mentioned the procurement alliance of 12 provinces (autonomous regions and municipalities) led by Henan Province.
The centralized procurement of orthopaedic trauma medical consumables was carried out, and the overall bid price of the selected products dropped significantly, and the profitability of the wholly-owned subsidiary Jiangsu Ideal Medical Technology Co.
, Ltd.
was greatly adversely affected
.
For companies that do not win the bid, they need to compete in the remaining smaller market share and face greater operational risks
.
Due to the introduction and implementation of the national centralized procurement policy for coronary stents, the price of domestic coronary stents has dropped significantly, and Sinomedical BuMA coronary stents have not been included in the scope of centralized procurement
.
According to the statistics of Sino Medical, its coronary artery business revenue in 2021 will be 59 million to 62 million yuan, a decrease of 188 million to 191 million yuan compared with the same period of the previous year.
722.
5%～-682.
48%
.
Table 2 Some 2021 annual report performance forecast loss listed machinery companies (data source: performance forecast of various listed machinery companies) Prospect forecast By the end of the "13th Five-Year Plan" period, a number of high-end products in the fields of medical equipment, pharmaceutical equipment, and production consumables will fill the domestic gap
.
The "14th Five-Year Plan" is the key five years for China's pharmaceutical industry to transform into an innovation-driven industry and achieve high-quality development
.
According to the forecast of the Southern Medical Economic Research Institute of the State Food and Drug Administration, the operating income of China's medical device industry will exceed 1.
15 trillion yuan in 2021, and a compound annual growth rate of about 13% will be achieved during the "14th Five-Year Plan" period.
The development scale of the equipment industry will reach a new level
.
During the interview, Cai Qiaowu, executive vice president and secretary general of Shenzhen Medical Device Industry Association, analyzed the industry trends in 2022 based on the overall performance of listed machinery companies in 2021
.
In his view, domestic substitution will be the biggest trend in the development of my country's medical device industry
.
On the other hand, with the continuous improvement of the quality of domestic device products, overseas export business drives the revenue of related companies
.
The novel coronavirus antigen detection kits of Jiu'an Medical, Rejing Bio and other companies have obtained foreign certification, which enables them to seize the opportunity of the international market, which is of great help to their development of overseas markets
.
But in the long run, if Chinese medical device companies want to achieve further development, the most important thing is to develop towards high-end, high-tech products
.
Anti-epidemic products such as novel coronavirus antigen detection kits are transient for the company's performance.
After the epidemic, there may be a sharp decline
.
"Only companies like Mindray Medical and Kaili Medical that really master the core technology and extend their products to the high-end market will be the hope for the future of Chinese products
.
" Cai Qiaowu pointed out
.
.
According to data from Oriental Fortune.
com, 58 listed machinery companies have announced their 2021 performance forecasts, accounting for 57.
43% of the total listed machinery companies
.
In general, the medical device industry, as one of China's high-tech industries, has a strong performance in 2021: among the listed companies that have announced their performance forecasts, 42 have pre-increased their performance, and nearly half of the companies have net profit attributable to their parent companies.
is expected to double
.
As of press time, 82 listed machinery companies have released the 2021 annual report appointment disclosure time, which will enter the peak period of annual report disclosure from mid-March to the end of April
.
The IVD field is unrivaled, and high-end products are shining brightly.
Judging from the expected year-on-year increase in net profit, the four companies of Rejing Bio, Zhijiang Bio, Kaili Medical, and Jiu'an Medical are expected to increase their performance by more than 3 times in 2021; Jiuqiang Bio , Kailitai, Aohua Endoscopy, Oriental Bio, Mingde Bio, Wantai Bio and other performance increased by more than 200%
.
Specifically, the substantial increase in overseas demand for new crown antigen detection reagents has led to a substantial increase in the performance of listed machinery companies in the IVD field
.
Rejing Bio is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%; Zhijiang Bio is expected to achieve a net profit of 930 million yuan in 2021, a year-on-year increase of 1705.
1%.
When analyzing the changes in performance, the main reason for the increase in profits was attributed to the approval of the novel coronavirus antigen detection kit abroad, which led to the explosive growth of the company's foreign trade orders and a major breakthrough in performance
.
The latest data from the Medical Insurance Chamber of Commerce shows that as of January 27, 2022, a total of 783 companies have produced new coronavirus detection reagents that have obtained foreign standard certification or registration
.
Jiu'an Medical, which has been eye-catching in the capital market since December last year, also benefited from the surge in sales of the new coronavirus (SARS-CoV-2) antigen home self-testing OTC kit products in the US market, which led to a substantial increase in operating performance in 2021.
It is expected to achieve a net profit of 900 million to 1.
2 billion yuan in the whole year, a year-on-year increase of 271.
4% to 395.
19%
.
In addition to the significant increase in foreign trade orders and related income of overseas new crown detection reagents due to the impact of the Delta and Omicron epidemics, some medical device companies have taken new steps in high-quality innovation and development, with considerable benefits
.
Taking Kaili Medical as an example, according to the statistics of Zhongcheng Digital, in 2021, a total of 4,394 purchasing units were monitored to announce the bidding results of medical endoscopes.
In terms of the winning amount of the winning brands, Kaili Medical ranked seventh
.
According to the forecast of Kaili Medical, the net profit for the whole year is 205 million to 255 million yuan, a year-on-year increase of 543.
12% to 651.
2%, and the revenue scale may reach a record high
.
As the products gain more clinical approvals, Aohua Endoscopy, another leading domestic endoscope company, will also deliver a satisfactory answer: in 2021, it is expected to achieve a net profit of 56 million to 63 million yuan, a year-on-year increase of 202.
54% to 240.
36%
.
Table 1 Some 2021 annual reports are expected to increase the performance of listed machinery companies.
The price of epidemic prevention products has returned, and centralized procurement has caused pain.
Compared with the unique scenery of foreign trade of new crown detection reagents, epidemic prevention products will gradually return to normal in 2021
.
According to statistics, 16 of the 58 listed machinery companies that have announced their 2021 performance forecasts have reported losses
.
Among them, Ogilvy Medical, which takes protective products as one of its main businesses, will be affected by the epidemic in 2020, and the price and volume of protective products will increase, resulting in a sharp increase in performance in 2020
.
In 2021, with the global epidemic prevention and control entering the normalization stage, Ogilvy Medical adjusted the business proportion of protective products, and the price and volume returned to normal levels.
62.
68%～-59.
83%
.
At the same time, with the continuous advancement of the procurement of high-value medical consumables, the coverage of centralized procurement has gradually expanded
.
In addition to the centralized procurement of coronary stents and artificial joints carried out by the state, the bidding work at the provincial level also involves related products such as intraocular lenses and coronary balloons
.
However, while the marketing costs of the winning products are reduced, they also face the test of profitability
.
For example, Kailitai predicts that it is expected to achieve a net profit of 140 million to 200 million yuan for the whole year, a year-on-year increase of 210.
64% to 258.
06%, but in the performance forecast, it also mentioned the procurement alliance of 12 provinces (autonomous regions and municipalities) led by Henan Province.
The centralized procurement of orthopaedic trauma medical consumables was carried out, and the overall bid price of the selected products dropped significantly, and the profitability of the wholly-owned subsidiary Jiangsu Ideal Medical Technology Co.
, Ltd.
was greatly adversely affected
.
For companies that do not win the bid, they need to compete in the remaining smaller market share and face greater operational risks
.
Due to the introduction and implementation of the national centralized procurement policy for coronary stents, the price of domestic coronary stents has dropped significantly, and Sinomedical BuMA coronary stents have not been included in the scope of centralized procurement
.
According to the statistics of Sino Medical, its coronary artery business revenue in 2021 will be 59 million to 62 million yuan, a decrease of 188 million to 191 million yuan compared with the same period of the previous year.
722.
5%～-682.
48%
.
Table 2 Some 2021 annual report performance forecast loss listed machinery companies (data source: performance forecast of various listed machinery companies) Prospect forecast By the end of the "13th Five-Year Plan" period, a number of high-end products in the fields of medical equipment, pharmaceutical equipment, and production consumables will fill the domestic gap
.
The "14th Five-Year Plan" is the key five years for China's pharmaceutical industry to transform into an innovation-driven industry and achieve high-quality development
.
According to the forecast of the Southern Medical Economic Research Institute of the State Food and Drug Administration, the operating income of China's medical device industry will exceed 1.
15 trillion yuan in 2021, and a compound annual growth rate of about 13% will be achieved during the "14th Five-Year Plan" period.
The development scale of the equipment industry will reach a new level
.
During the interview, Cai Qiaowu, executive vice president and secretary general of Shenzhen Medical Device Industry Association, analyzed the industry trends in 2022 based on the overall performance of listed machinery companies in 2021
.
In his view, domestic substitution will be the biggest trend in the development of my country's medical device industry
.
On the other hand, with the continuous improvement of the quality of domestic device products, overseas export business drives the revenue of related companies
.
The novel coronavirus antigen detection kits of Jiu'an Medical, Rejing Bio and other companies have obtained foreign certification, which enables them to seize the opportunity of the international market, which is of great help to their development of overseas markets
.
But in the long run, if Chinese medical device companies want to achieve further development, the most important thing is to develop towards high-end, high-tech products
.
Anti-epidemic products such as novel coronavirus antigen detection kits are transient for the company's performance.
After the epidemic, there may be a sharp decline
.
"Only companies like Mindray Medical and Kaili Medical that really master the core technology and extend their products to the high-end market will be the hope for the future of Chinese products
.
" Cai Qiaowu pointed out
.
